Human Papillomavirus Infections - Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 6 PAGES: 99

Human Papillomavirus Infections - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Human Papillomavirus Infections - Pipeline Review, H2 2011', provides an overview of the Human Papillomavirus Infections therapeutic pipeline. This report provides information on the therapeutic development for Human Papillomavirus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections. 'Human Papillomavirus Infections - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Human Papillomavirus Infections.
- A review of the Human Papillomavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Human Papillomavirus Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under

More Info
									Human Papillomavirus Infections – Pipeline Review, H2 2011




     Human Papillomavirus Infections - Pipeline Review,
                        H2 2011
                                                                                          Reference Code: GMDHC1463IDB

                                                                                          Publication Date: October 2011




Human Papillomavirus Infections – Pipeline Review, H2 2011                                                       GMDHC1463IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                  Page(1)
Human Papillomavirus Infections – Pipeline Review, H2 2011



Ta b le o f Co n te n ts
Table of Contents ..................................................................................................................................................................................................... 2
      List of Tables...................................................................................................................................................................................................... 7
      List of Figures .................................................................................................................................................................................................... 8
Introduction .............................................................................................................................................................................................................. 9
      Global Markets Direct Report Coverage ............................................................................................................................................................. 9
Human Papillomavirus Infections Overview .............................................................................................................................................................10
Therapeutics Development ......................................................................................................................................................................................11
      An Overview of Pipeline Products for Human Papillomavirus Infections ............................................................................................................11
Human Papillomavirus Infections Therapeutics under Development by Companies ................................................................................................13
Human Papillomavirus Infections Therapeutics under Investigation by Universities/Institutes ..................................................................................15
Late Stage Products ................................................................................................................................................................................................17
      Comparative Analysis .......................................................................................................................................................................................17
Mid Clinical Stage Products .....................................................................................................................................................................................18
      Comparative Analysis .......................................................................................................................................................................................18
Early Clinical Stage Products ..................................................................................................................................................................................19
      Comparative Analysis .......................................................................................................................................................................................19
Discovery and Pre-Clinical Stage Products..............................................................................................................................................................20
      Comparative Analysis .......................................................................................................................................................................................20
Human Papillomavirus Infections Therapeutics - Products under Development by Companies ...............................................................................21
Human Papillomavirus Infections Therapeutics - Products under Investigation by Universities/Institutes .................................................................23
Companies Involved in Human Papillomavirus Infections Therapeutics Development .............................................................................................24
      Johnson & Johnson...........................................................................................................................................................................................24
      F. Hoffmann-La Roche Ltd. ...............................................................................................................................................................................24
      Helix BioPharma Corp. ......................................................................................................................................................................................25
      Merck & Co., Inc................................................................................................................................................................................................25
      MediGene AG ...................................................................................................................................................................................................26
      Bio-Bridge Science, Inc. ....................................................................................................................................................................................26
      Amarillo Biosciences, Inc. .................................................................................................................................................................................27
      Starpharma Holdings Limited ............................................................................................................................................................................27
      Transgene SA ...................................................................................................................................................................................................28
      Nutri Pharma ASA .............................................................................................................................................................................................28
      BioMAS Ltd. ......................................................................................................................................................................................................29
      ApoImmune, Inc. ...............................................................................................................................................................................................29
      PDS Biotechnology Corporation ........................................................................................................................................................................30
      Lumavita AG .....................................................................................................................................................................................................30
      Graceway Pharmaceuticals, LLC ......................................................................................................................................................................31
      ImmunoVaccine Technologies Inc. ....................................................................................................................................................................31
      BT PHARMA .....................................................................................................................................................................................................32
      iBio, Inc. ............................................................................................................................................................................................................32
      Genetic Immunity, LLC ......................................................................................................................................................................................33
      IRX Therapeutics, Inc. .......................................................................................................................................................................................33
      Moberg Derma AB ............................................................................................................................................................................................34
      Inviragen, Inc. ...................................................................................................................................................................................................34
Human Papillomavirus Infections - Therapeutics Assessment .................................................................................................................................35
      Assessment by Monotherapy Products .............................................................................................................................................................35
      Assessment by Combination Products ..............................................................................................................................................................36
      Assessment by Route of Administration ............................................................................................................................................................37


Human Papillomavirus Infections – Pipeline Review, H2 2011                                                                                                      GMDHC1463IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                                  Page(2)
Human Papillomavirus Infections – Pipeline Review, H2 2011


      Assessment by Molecule Type ..........................................................................................................................................................................39
Drug Profiles ...........................................................................................................................................................................................................41
      PDS0101 - Drug Profile .....................................................................................................................................................................................41
            Product Description ....................................................................................................................................................................................41
            Mechanism of Action...................................................................................................................................................................................41
            R&D Progress .............................................................................................................................................................................................41
      BAMLET Topical Gel - Drug Profile ...................................................................................................................................................................42
            Product Description ....................................................................................................................................................................................42
            Mechanism of Action...................................................................................................................................................................................42
            R&D Progress .............................................................................................................................................................................................42
      BAMLET Topical Gel - Drug Profile ...................................................................................................................................................................43
            Product Description ....................................................................................................................................................................................43
            Mechanism of Action...................................................................................................................................................................................43
            R&D Progress .............................................................................................................................................................................................43
      Interferon Alpha-2b - Drug Profile ......................................................................................................................................................................44
            Product Description ....................................................................................................................................................................................44
            Mechanism of Action...................................................................................................................................................................................44
            R&D Progress .............................................................................................................................................................................................44
      HPV Vaccine - Drug Profile ...............................................................................................................................................................................46
            Product Description ....................................................................................................................................................................................46
            Mechanism of Action...................................................................................................................................................................................46
            R&D Progress .............................................................................................................................................................................................46
      Interferon Alpha - Drug Profile ...........................................................................................................................................................................47
            Product Description ....................................................................................................................................................................................47
            Mechanism of Action...................................................................................................................................................................................47
            R&D Progress .............................................................................................................................................................................................47
      ApoVax104-HPV - Drug Profile .........................................................................................................................................................................48
            Product Description ....................................................................................................................................................................................48
            Mechanism of Action...................................................................................................................................................................................48
            R&D Progress .............................................................................................................................................................................................48
      LMV-601 - Drug Profile......................................................................................................................................................................................49
            Product Description ....................................................................................................................................................................................49
            Mechanism of Action...................................................................................................................................................................................49
            R&D Progress .............................................................................................................................................................................................49
      IRX-3 - Drug Profile ...........................................................................................................................................................................................50
            Product Description ....................................................................................................................................................................................50
            Mechanism of Action...................................................................................................................................................................................50
            R&D Progress .............................................................................................................................................................................................50
      V503 - Drug Profile............................................................................................................................................................................................51
            Product Description ....................................................................................................................................................................................51
            Mechanism of Action...................................................................................................................................................................................51
            R&D Progress .............................................................................................................................................................................................51
      Imiquimod - Drug Profile....................................................................................................................................................................................52
            Product Description ....................................................................................................................................................................................52
            Mechanism of Action...................................................................................................................................................................................52
            R&D Progress .............................................................................................................................................................................................52
      AS101 - Drug Profile .........................................................................................................................................................................................53
            Product Description ....................................................................................................................................................................................53




Human Papillomavirus Infections – Pipeline Review, H2 2011                                                                                                   GMDHC1463IDB / Pub October 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                                              Page(3)
Human Papillomavirus Infections – Pipeline Review, H2 2011


          Mechanism of Action...................................................................................................................................................................................53
          R&D Progress .............................................................................................................................................................................................53
     RO5217790 - Drug Profile .................................................................................................................................................................................55
          Product Description ....................................................................................................................................................................................55
          Mechanism of Action...................................................................................................................................................................................55
          R&D Progress .............................................................................................................................................................................................55
     Isotretinoin + Interferon Alfa-2a - Drug Profile ...................................................................................................................................................56
          Product Description ....................................................................................................................................................................................56
          Mechanism of Action...................................................................................................................................................................................56
          R&D Progress .............................................................................................................................................................................................56
     Candida Antigen - Drug Profile ..........................................................................................................................................................................57
          Product Description ....................................................................................................................................................................................57
          Mechanism of Action...................................................................................................................................................................................57
          R&D Progress .............................................................................................................................................................................................57
     GS-9191 - Drug Profile ......................................................................................................................................................................................58
          Product Description ....................................................................................................................................................................................58
          Mechanism of Action...................................................................................................................................................................................58
          R&D Progress .............................................................................................................................................................................................58
     Human Papillomavirus Quadrivalent Vaccine - Drug Profile ..............................................................................................................................59
          Product Description ....................................................................................................................................................................................59
          Mechanism of Action...................................................................................................................................................................................59
          R&D Progress .............................................................................................................................................................................................59
     Resiquimod - Drug Profile .................................................................................................................................................................................61
          Product Description ....................................................................................................................................................................................61
          Mechanism of Action...................................................................................................................................................................................61
          R&D Progress .............................................................................................................................................................................................61
     VivaGel - Drug Profile .......................................................................................................................................................................................62
          Product Description ....................................................................................................................................................................................62
          Mechanism of Action...................................................................................................................................................................................62
          R&D Progress .............................................................................................................................................................................................62
     V504 + Gardasil - Drug Profile...........................................................................................................................................................................63
          Product Description ....................................................................................................................................................................................63
          Mechanism of Action...................................................................................................................................................................................63
          R&D Progress .............................................................................................................................................................................................63
     V505 - Drug Profile............................................................................................................................................................................................64
          Product Description ....................................................................................................................................................................................64
          Mechanism of Action...........................................................
								
To top